RUBRAMIN PC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Just now · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBRAMIN PC is an injectable small-molecule product approved by Bristol Myers Squibb in 1950. The specific indication and mechanism of action are not currently documented in available data, limiting clinical characterization. This legacy product represents a historical pharmaceutical asset with over 70 years of market presence.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); minimal commercial headcount likely as brand enters maturity phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RUBRAMIN PC offers minimal career momentum given zero linked job openings and approaching LOE status. Roles available are typically in lifecycle management, compliance, and supply optimization rather than growth-oriented functions.
Brand Manager (Mature/Declining Assets)Field Sales Representative
Worked on RUBRAMIN PC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.